Log In
Print
BCIQ
Print
Print this Print this
 

oral semaglutide (NN9924, OG217SC)

  Manage Alerts
Collapse Summary General Information
Company Novo Nordisk A/S
DescriptionOral long-acting glucagon-like peptide-1 (GLP-1) analog
Molecular Target Glucagon-like peptide-1 receptor (GLP-1R) (GLP1R)
Mechanism of ActionGlucagon-like peptide-1 (GLP-1) receptor agonist
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationDiabetes
Indication DetailsTreat Type II diabetes
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today